Showing 3641-3650 of 4063 results for "".
- Slit Lamp Breath Shields Proven to Minimize Spread of Droplets That Can Carry Coronavirus During Eye Examshttps://modernod.com/news/slit-lamp-breath-shields-proven-to-minimize-spread-of-droplets-that-can-carry-coronavirus-during-eye-exams/2478567/Eye exams require close physical contact between patients and physicians, which is not an issue, until a pandemic strikes. Last spring, ophthalmologists began improvising with various forms and sizes of plastic sheeting attached to exam equipment to help protect both the patient and them from the
- Zeiss Presents Integrated Workflow Advancements at AAOhttps://modernod.com/news/zeiss-presents-integrated-workflow-advancements-at-aao/2478534/The Medical Technology segment of Zeiss will present its latest integrated diagnostic and surgical advancements at the 2020 American Academy of Ophthalmology’s (AAO) Annual Meeting taking place virtually from Nov. 13-15. Zeiss will also be hosting multiple indu
- EU Seals Deal For Up to 300 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/The European Commission on Wednesday said it has finalized an advance purchase agreement with Pfizer and BioNTech for the initial supply of 200 million doses of their experimental COVID-19 vaccine, with an option to request up to a 100 million more. The announcement comes days after the companies
- New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtualhttps://modernod.com/news/new-data-for-thyroid-eye-disease-treatment-tepezza-to-be-presented-at-aao-virtual/2478527/Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) data will be presented at the American Academy of Ophthalmology Annual Meeting, Nov. 13-15, 2020. Tepezza is the first and only medicine approved by the FDA for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and v
- Samsung Bioepis Announces 1-year Results From Phase 3 Study of SB11 Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-1-year-results-from-phase-3-study-of-sb11-proposed-lucentis-biosimilar/2478526/Samsung Bioepis announced 1-year results from the phase 3 study on SB11, a proposed biosimilar to Lucentis (ranibizumab), in patients with neovascular age-related macular degeneration (AMD). This data will be presented for the first time at the American Academy of Ophthalmology (AAO) 2020 Virtual
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Diseasehttps://modernod.com/news/aao-data-experimental-rna-based-drug-addresses-the-underlying-cause-of-rare-eye-disease/2478509/At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss. P
- Staar Surgical Begins Commercialization of EVO Viva Presbyopia Correcting Lenshttps://modernod.com/news/staar-surgical-begins-commercialization-of-evo-viva-presbyopia-correcting-lens/2478495/Staar Surgical announced the initial commercialization of its EVO Viva presbyopia correcting lens including the first patient implant. “The first patient received his EVO Viva lenses on October 23 in Belgium from Dr. Erik Mertens, and we are delighted to hear from Dr. Mertens that the pati
- Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code From the AMA for the Insertion of Intracanalicular Insertshttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-a-permanent-category-i-cpt-code-from-the-ama-for-the-insertion-of-intracanalicular-inserts/2478492/Ocular Therapeutix announced that its application for the creation of a Category I Current Procedural Terminology (CPT) procedure code, presented at the October 2020 American Medical Association (AMA) CPT Editorial Panel meeting, has been granted. The Panel has accepted the addition of a permanen
- Regenxbio to Receive $80 Million Milestone Payment from Novartishttps://modernod.com/news/regenxbio-to-receive-80-million-milestone-payment-from-novartis/2478475/Regenxbio announced that it will receive a milestone payment of $80 million from Novartis based upon the achievement of $1 billion in cumulative net sales of Zolgensma. Regenxbio expects to recognize this revenue in the third quarter of 2020. “Zolgensma is a transformative, one-time